These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 20679439)

  • 1. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility.
    Bishop AL; Schild S; Patimalla B; Klein B; Camilli A
    Infect Immun; 2010 Oct; 78(10):4402-20. PubMed ID: 20679439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera.
    Schild S; Nelson EJ; Bishop AL; Camilli A
    Infect Immun; 2009 Jan; 77(1):472-84. PubMed ID: 19001078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice.
    Schild S; Nelson EJ; Camilli A
    Infect Immun; 2008 Oct; 76(10):4554-63. PubMed ID: 18678672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model.
    Roy N; Barman S; Ghosh A; Pal A; Chakraborty K; Das SS; Saha DR; Yamasaki S; Koley H
    FEMS Immunol Med Microbiol; 2010 Oct; 60(1):18-27. PubMed ID: 20528929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of mice with vibrio cholerae outer-membrane vesicles protects against hyperinfectious challenge and blocks transmission.
    Bishop AL; Tarique AA; Patimalla B; Calderwood SB; Qadri F; Camilli A
    J Infect Dis; 2012 Feb; 205(3):412-21. PubMed ID: 22147790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
    Kamruzzaman M; Kelly M; Charles RC; Harris JB; Calderwood SB; Akter A; Biswas R; Kaisar MH; Bhuiyan TR; Ivers LC; Ternier R; Jerome JG; Pfister HB; Lu X; Soliman SE; Ruttens B; Saksena R; Mečárová J; Čížová A; Qadri F; Bystrický S; Kováč P; Xu P; Ryan ET
    mSphere; 2021 Aug; 6(4):e0011421. PubMed ID: 34232076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunity Provided by an Outer Membrane Vesicle Cholera Vaccine Is Due to O-Antigen-Specific Antibodies Inhibiting Bacterial Motility.
    Wang Z; Lazinski DW; Camilli A
    Infect Immun; 2017 Jan; 85(1):. PubMed ID: 27795359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.
    Leitner DR; Feichter S; Schild-Prüfert K; Rechberger GN; Reidl J; Schild S
    Infect Immun; 2013 Jul; 81(7):2379-93. PubMed ID: 23630951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.
    Tarique AA; Kalsy A; Arifuzzaman M; Rollins SM; Charles RC; Leung DT; Harris JB; Larocque RC; Sheikh A; Bhuiyan MS; Saksena R; Clements JD; Calderwood SB; Qadri F; Kovác P; Ryan ET
    Clin Vaccine Immunol; 2012 Apr; 19(4):594-602. PubMed ID: 22357651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of O-specific polysaccharide responses in patients following infection with
    Kaisar MH; Kelly M; Kamruzzaman M; Bhuiyan TR; Chowdhury F; Khan AI; LaRocque RC; Calderwood SB; Harris JB; Charles RC; Čížová A; Mečárová J; Korcová J; Bystrický S; Kováč P; Xu P; Qadri F; Ryan ET
    mSphere; 2023 Oct; 8(5):e0025523. PubMed ID: 37646517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh.
    Akter A; Dash P; Aktar A; Jahan SR; Afrin S; Basher SR; Hakim A; Lisa AK; Chowdhury F; Khan AI; Xu P; Charles RC; Kelly M; Kováč P; Harris JB; Bhuiyan TR; Calderwood SB; Ryan ET; Qadri F
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007634. PubMed ID: 31369553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of Vibrio cholerae outer membrane vesicles secreted at various environmental conditions.
    Adriani R; Mousavi Gargari SL; Nazarian S; Sarvary S; Noroozi N
    Vaccine; 2018 Jan; 36(2):322-330. PubMed ID: 29191736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
    Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunochemical characterization of an Ogawa-Inaba common antigenic determinant of Vibrio cholerae O1.
    Villeneuve S; Boutonnier A; Mulard LA; Fournier JM
    Microbiology (Reading); 1999 Sep; 145 ( Pt 9)():2477-2484. PubMed ID: 10517600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
    Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
    Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The excretion pattern and protective capacity in rabbits orally immunized with attenuated strains of Vibrio cholerae O1 biotype El Tor].
    García Sánchez HM; García Imia L; Oliva Hernández R; Pérez Quiñoy JL; Cedré Marrero B; Domínguez Iriarte R; Benítez Robles J
    Rev Cubana Med Trop; 1998; 50(2):115-9. PubMed ID: 10349429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice.
    Sayeed MA; Bufano MK; Xu P; Eckhoff G; Charles RC; Alam MM; Sultana T; Rashu MR; Berger A; Gonzalez-Escobedo G; Mandlik A; Bhuiyan TR; Leung DT; LaRocque RC; Harris JB; Calderwood SB; Qadri F; Vann WF; Kováč P; Ryan ET
    PLoS Negl Trop Dis; 2015; 9(7):e0003881. PubMed ID: 26154421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.